American International Group’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-44,180
| Closed | -$1.22M | – | 1795 |
|
|
2024
Q1 | $1.22M | Buy |
44,180
+325
| +0.7% | +$9.03K | ﹤0.01% | 1202 |
|
|
2023
Q4 | $1.34M | Sell |
43,855
-176
| -0.4% | -$5.06K | 0.01% | 1156 |
|
|
2023
Q3 | $1.39M | Buy |
44,031
+1,565
| +4% | +$60.7K | 0.01% | 1080 |
|
|
2023
Q2 | $1.73M | Buy |
42,466
+2,457
| +6% | +$99.6K | 0.01% | 1010 |
|
|
2023
Q1 | $1.49M | Sell |
40,009
-193
| -0.5% | -$7.57K | 0.01% | 1036 |
|
|
2022
Q4 | $1.4M | Buy |
40,202
+4,402
| +12% | +$209K | 0.01% | 1059 |
|
|
2022
Q3 | $2M | Buy |
35,800
+505
| +1% | +$31.3K | 0.01% | 932 |
|
|
2022
Q2 | $1.83M | Buy |
35,295
+662
| +2% | +$33.6K | 0.01% | 971 |
|
|
2022
Q1 | $2.52M | Sell |
34,633
-2,438
| -7% | -$207K | 0.01% | 951 |
|
|
2021
Q4 | $4.38M | Sell |
37,071
-630
| -2% | -$78.9K | 0.02% | 842 |
|
|
2021
Q3 | $5.06M | Buy |
37,701
+1,905
| +5% | +$288K | 0.03% | 780 |
|
|
2021
Q2 | $5.8K | Buy |
35,796
+3,823
| +12% | +$298K | 0.02% | 798 |
|
|
2021
Q1 | $2.57K | Buy |
31,973
+2,845
| +10% | +$191K | 0.01% | 1008 |
|
|
2020
Q4 | $1.58K | Sell |
29,128
-836
| -3% | -$30.4K | 0.01% | 1179 |
|
|
2020
Q3 | $596K | Buy |
29,964
+3,158
| +12% | +$65.8K | ﹤0.01% | 1508 |
|
|
2020
Q2 | $563K | Buy |
26,806
+3,920
| +17% | +$66.6K | ﹤0.01% | 1534 |
|
|
2020
Q1 | $280K | Sell |
22,886
-1,323
| -5% | -$17.8K | ﹤0.01% | 1722 |
|
|
2019
Q4 | $355K | Sell |
24,209
-203
| -0.8% | -$2.83K | ﹤0.01% | 1888 |
|
|
2019
Q3 | $326K | Buy |
24,412
+1,263
| +5% | +$20.1K | ﹤0.01% | 1889 |
|
|
2019
Q2 | $379K | Buy |
23,149
+1,962
| +9% | +$30.8K | ﹤0.01% | 1854 |
|
|
2019
Q1 | $362K | Sell |
21,187
-687
| -3% | -$10.2K | ﹤0.01% | 1886 |
|
|
2018
Q4 | $299K | Sell |
21,874
-168
| -0.8% | -$3.12K | ﹤0.01% | 1953 |
|
|
2018
Q3 | $631K | Buy |
22,042
+397
| +2% | +$11.6K | ﹤0.01% | 1741 |
|
|
2018
Q2 | $592K | Buy |
21,645
+10,991
| +103% | +$266K | ﹤0.01% | 1716 |
|
|
2018
Q1 | $225K | Sell |
10,654
-573
| -5% | -$14.1K | ﹤0.01% | 2186 |
|
|
2017
Q4 | $216K | Buy |
11,227
+1,718
| +18% | +$39.7K | ﹤0.01% | 2277 |
|
|
2017
Q3 | $236K | Buy |
9,509
+711
| +8% | +$13.4K | ﹤0.01% | 2202 |
|
|
2017
Q2 | $141K | Buy |
8,798
+4,503
| +105% | +$62.9K | ﹤0.01% | 2499 |
|
|
2017
Q1 | $61K | Buy |
4,295
+281
| +7% | +$3.77K | ﹤0.01% | 2780 |
|
|
2016
Q4 | $53K | Sell |
4,014
-12
| -0.3% | -$180 | ﹤0.01% | 2845 |
|
|
2016
Q3 | $68.5K | Buy |
4,026
+6
| +0.1% | +$116 | ﹤0.01% | 2806 |
|
|
2016
Q2 | $85.8K | Buy |
+4,020
| New | +$107K | ﹤0.01% | 2718 |
|
Other funds holding NTLA
AIM
DTC
NAMA
American International Group's NTLA Position: Q2 2024 in Review
American International Group sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 44,180 shares — an estimated $1.22M sold.
American International Group first reported a position in NTLA in Q2 2016 and held it in 32 quarters. The position peaked at $5.06M in Q3 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.
- American International Group reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
- American International Group sold 44,180 Intellia Therapeutics shares in Q2 2024, an estimated $1.22M.
- American International Group first reported a position in Intellia Therapeutics in Q2 2016 and held it in 32 quarters.
- American International Group's Intellia Therapeutics position peaked at $5.06M in Q3 2021.
- 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.
Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.